{"Abstract": [0], "Lung": [1], "cancer": [2, 21, 53, 118, 159, 195, 201, 214], "is": [3, 34, 47, 152], "the": [4, 10, 15, 38, 50, 84, 99, 175, 183, 187, 204, 208, 219, 236, 251], "primary": [5], "cause": [6], "of": [7, 40, 86, 148, 182, 210, 222, 239], "mortality": [8], "in": [9, 83, 91, 111, 186, 190, 212, 250], "United": [11], "States": [12], "and": [13, 28, 69, 106, 128, 197, 235], "around": [14], "globe.": [16], "Therapeutic": [17, 158], "options": [18], "for": [19], "lung": [20, 87, 104, 117, 155, 194, 200, 213], "treatment": [22, 41, 54, 85, 241], "include": [23], "surgery,": [24], "radiation": [25], "therapy,": [26], "chemotherapy,": [27], "targeted": [29], "drug": [30], "therapy.": [31], "Medical": [32], "management": [33], "often": [35], "associated": [36, 100, 107, 153], "with": [37, 133, 154, 162, 226], "development": [39], "resistance": [42], "leading": [43], "to": [44, 52, 56, 65, 246], "relapse.": [45], "Immunotherapy": [46], "profoundly": [48], "altering": [49], "approach": [51], "owing": [55], "its": [57], "tolerable": [58], "safety": [59], "profile,": [60], "sustained": [61, 129], "therapeutic": [62, 170], "response": [63], "due": [64], "immunological": [66], "memory": [67], "generation,": [68], "effectiveness": [70], "across": [71], "a": [72, 121, 146, 179], "broad": [73], "patient": [74], "population.": [75], "Different": [76], "tumor-specific": [77], "vaccination": [78], "strategies": [79], "are": [80, 109, 243], "gaining": [81], "ground": [82], "cancer.": [88], "Recent": [89, 114], "advances": [90], "adoptive": [92], "cell": [93, 193, 199], "therapy": [94, 224], "(CAR": [95], "T,": [96], "TCR,": [97], "TIL),": [98], "clinical": [101, 231], "trials": [102, 115], "on": [103, 116], "cancer,": [105], "hurdles": [108], "discussed": [110], "this": [112, 173, 240], "review.": [113], "patients": [119], "(without": [120], "targetable": [122], "oncogenic": [123], "driver": [124], "alteration)": [125], "reveal": [126], "significant": [127, 233], "responses": [130], "when": [131], "treated": [132], "programmed": [134], "death-1/programmed": [135], "death-ligand": [136], "1": [137], "(PD-1/PD-L1)": [138], "checkpoint": [139, 164], "blockade": [140], "immunotherapies.": [141], "Accumulating": [142], "evidence": [143], "indicates": [144], "that": [145], "loss": [147], "effective": [149], "anti-tumor": [150], "immunity": [151], "tumor": [156], "evolution.": [157], "vaccines": [160], "combined": [161], "immune": [163], "inhibitors": [165], "(ICI)": [166], "can": [167], "achieve": [168], "better": [169], "effects.": [171], "To": [172], "end,": [174], "present": [176], "article": [177], "encompasses": [178], "detailed": [180], "overview": [181], "recent": [184], "developments": [185], "immunotherapeutic": [188], "landscape": [189], "targeting": [191], "small": [192], "(SCLC)": [196], "non-small": [198], "(NSCLC).": [202], "Additionally,": [203], "review": [205], "also": [206, 244], "explores": [207], "implication": [209], "nanomedicine": [211], "immunotherapy": [215, 227], "as": [216, 218], "well": [217], "combinatorial": [220], "application": [221], "traditional": [223], "along": [225], "regimens.": [228], "Finally,": [229], "ongoing": [230], "trials,": [232], "obstacles,": [234], "future": [237], "outlook": [238], "strategy": [242], "highlighted": [245], "boost": [247], "further": [248], "research": [249], "field.": [252]}